> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves FoundationOne Liquid Biopsy Test
- URL: https://www.fdaweb.com/fda-approves-foundationone-liquid-biopsy-test/
- Published: 2020-08-27T12:00:00.000Z
- Updated: 2026-09-14T16:26:49.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5147531

FDA has approved Foundation Medicine’s FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test. The company [says](https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721?ref=fdaweb.com) the approval includes companion diagnostic claims for Rubraca (rucaparib), the first PARP (poly ADP ribose polymerase) inhibitor approved in a prostate cancer setting, and three tyrosine kinase inhibitors for non-small cell lung cancer. FoundationOne Liquid CDx analyzes more than 300 genes and genomic signatures to help inform treatment decisions for all solid tumor cancers, the company says.